{"entity":{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","aka":[],"tldr":"Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease.","summary":"Ramez Eskander was principal investigator of NRG-GY018 (KEYNOTE-868), which showed adding pembrolizumab to carboplatin-paclitaxel improves progression-free survival in advanced or recurrent endometrial cancer in both mismatch repair-deficient and proficient populations, published alongside RUBY to establish chemo-immunotherapy as first-line standard. He leads gynaecologic oncology trials at UC San Diego and within NRG Oncology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eskander%20RN%5BAuthor%5D%20endometrial%20pembrolizumab"}],"tags":["endometrial","immunotherapy","nrg-oncology"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":["gog-foundation"],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":["nrg-gy018-keynote-868"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego Moores Cancer Center","institutionId":"ucsd-moores","specialisms":["Endometrial cancer","Immunotherapy","Gynaecologic oncology surgery","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eskander%20RN%5BAuthor%5D%20endometrial%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer (NRG-GY018)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2302312"},{"title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer: overall survival and progression-free survival by mismatch repair status","journal":"JCO","year":2025}],"orcid":"0000-0002-2101-1935"},"route":"/people/ramez-eskander/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"}],"institution":[{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/"}],"trial":[{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/"}]}}